Booming Omics in Schistosoma

Type Article
Date 2021-01
Language English
Author(s) Le Govic Yohann1, Gourbal Benjamin2, Boissier Jérôme3
Affiliation(s) 1 : Department of Medical Parasitology and Mycology, Amiens University Hospital, Amiens, France
2 : Host–Pathogen Interaction Study Group (GEIHP, EA 3142), UNIV Angers, UNIV Brest, Federative Structure of Research 'Cellular Interactions and Therapeutic Applications', SFR 4208 ICAT, Angers, France
3 : IHPE, University of Montpellier, CNRS, Ifremer, University of Perpignan Via Domitia, Perpignan, France
Source Trends In Parasitology (1471-4922) (Elsevier BV), 2021-01 , Vol. 37 , N. 1 , P. 6-8
DOI 10.1016/

Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel. By using postgenomic technologies, Wendt et al. and Wang et al. deciphered the function of several genes required for worm survival and pathogenesis, which opens the way for the development of innovative parasite-targeted therapies.

Full Text
File Pages Size Access
2 763 KB Access on demand
Author's final draft 7 459 KB Open access
Top of the page